Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02791334
Title A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (PACT)
Acronym PACT
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eli Lilly and Company
Indications
Therapies
Age Groups: adult
Covered Countries USA | FRA | ESP | CAN | BEL

Facility Status City State Zip Country Details
Tennessee Oncology PLLC Nashville Tennessee 37203 United States Details
University of Texas MD Anderson Cancer Center Houston Texas 77030 United States Details
The START Center for Cancer Care San Antonio Texas 78229 United States Details
Cliniques Universitaires Saint-Luc Brussels 1200 Belgium Details
Universitair Ziekenhuis Antwerpen Edegem 2650 Belgium Details
Princess Margaret Hospital Toronto Ontario M5TY 2M9 Canada Details
Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest Bordeaux 33076 France Details
Gustave Roussy Villejuif Cedex 94805 France Details
Seoul National University Hospital Seoul 03080 Korea, Republic of Details
Severance Hospital Yonsei University Health System Seoul 03722 Korea, Republic of Details
Hospital Universitario Fundación Jiménez Díaz Madrid 28040 Spain Details
Hospital Madrid Norte Sanchinarro Madrid 28050 Spain Details
National Cheng Kung University Hospital Tainan 70403 Taiwan Details
National Taiwan University Hospital Taipei 10048 Taiwan Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field